BPMC vs. ONC, BNTX, TEVA, SMMT, GMAB, ITCI, RDY, ASND, VTRS, and QGEN
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
Blueprint Medicines vs. Its Competitors
Blueprint Medicines (NASDAQ:BPMC) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.
Blueprint Medicines presently has a consensus target price of $128.06, indicating a potential downside of 0.15%. BeOne Medicines has a consensus target price of $319.00, indicating a potential upside of 19.42%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Blueprint Medicines.
In the previous week, BeOne Medicines had 11 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for BeOne Medicines and 7 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.72 beat BeOne Medicines' score of -0.03 indicating that Blueprint Medicines is being referred to more favorably in the media.
BeOne Medicines has a net margin of -9.40% compared to Blueprint Medicines' net margin of -27.70%. BeOne Medicines' return on equity of -7.55% beat Blueprint Medicines' return on equity.
Blueprint Medicines has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Blueprint Medicines has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.
48.6% of BeOne Medicines shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
BeOne Medicines beats Blueprint Medicines on 10 of the 17 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:BPMC) was last updated on 6/25/2025 by MarketBeat.com Staff
Buy BPMC Stock Free BPMC Stock Alerts